Systematic Financial Management LP Boosts Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Systematic Financial Management LP increased its stake in Supernus Pharmaceuticals by 46.7% during the first quarter, acquiring an additional 53,004 shares for a total of 166,504 shares valued at approximately $5.45 million.
• CEO Jack A. Khattar sold 140,000 shares of Supernus, resulting in an 11.96% decrease in his ownership, while the stock has seen significant insider sales totaling over $6.42 million in the past ninety days.
• Analysts have revised their target prices for Supernus Pharmaceuticals, with Cantor Fitzgerald raising theirs to $46.00 and Zacks upgrading from a "strong sell" to a "hold" rating, indicating a consensus of "Moderate Buy" from analysts.

Systematic Financial Management LP raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 46.7% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 166,504 shares of the specialty pharmaceutical company's stock after acquiring an additional 53,004 shares during the period. Systematic Financial Management LP owned approximately 0.30% of Supernus Pharmaceuticals worth $5,453,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vident Advisory LLC raised its position in shares of Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock valued at $520,000 after purchasing an additional 309 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Supernus Pharmaceuticals by 2.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock valued at $480,000 after acquiring an additional 350 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth about $25,000. PNC Financial Services Group Inc. increased its position in shares of Supernus Pharmaceuticals by 4.7% in the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock worth $527,000 after purchasing an additional 726 shares during the last quarter. Finally, Quantinno Capital Management LP raised its stake in Supernus Pharmaceuticals by 11.5% in the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after purchasing an additional 864 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 1.7%

SUPN stock traded up $0.75 on Wednesday, hitting $45.07. The company had a trading volume of 680,753 shares, compared to its average volume of 641,327. The stock's 50-day simple moving average is $35.88 and its 200 day simple moving average is $33.77. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of 39.19 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60.

Insider Transactions at Supernus Pharmaceuticals

In related news, Director Frederick M. Hudson sold 7,457 shares of the company's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the sale, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Timothy C. Dec sold 11,780 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares in the company, valued at $55,434.54. This represents a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 179,606 shares of company stock valued at $7,617,005. Company insiders own 8.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.